RWMA Stock Overview
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.39 |
| 52 Week High | US$5.57 |
| 52 Week Low | US$1.12 |
| Beta | 1.2 |
| 1 Month Change | -5.83% |
| 3 Month Change | 13.93% |
| 1 Year Change | -35.65% |
| 3 Year Change | -83.91% |
| 5 Year Change | -97.22% |
| Change since IPO | -98.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| RWMA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.4% | 2.6% | 1.2% |
| 1Y | -35.6% | -8.3% | 2.0% |
Return vs Industry: RWMA underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: RWMA underperformed the German Market which returned 2% over the past year.
Price Volatility
| RWMA volatility | |
|---|---|
| RWMA Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RWMA has not had significant price volatility in the past 3 months.
Volatility Over Time: RWMA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 237 | Mark Strobeck | www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.
Rockwell Medical, Inc. Fundamentals Summary
| RWMA fundamental statistics | |
|---|---|
| Market cap | €39.94m |
| Earnings (TTM) | -€8.03m |
| Revenue (TTM) | €78.16m |
0.5x
P/S Ratio-5.0x
P/E RatioIs RWMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RWMA income statement (TTM) | |
|---|---|
| Revenue | US$83.61m |
| Cost of Revenue | US$74.91m |
| Gross Profit | US$8.70m |
| Other Expenses | US$17.29m |
| Earnings | -US$8.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 10.41% |
| Net Profit Margin | -10.27% |
| Debt/Equity Ratio | 40.1% |
How did RWMA perform over the long term?
See historical performance and comparison